Payment overview · 2025
General Payments
$616.00
19 reported records · 11 companies
Healthcare provider profile · identity verified
Karrar Husain, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GREENSBORO, NC · NPI 1407925696
Verified facts
What the public records show
CMS Open Payments records show Karrar Husain, MD received $616.00 in general payments during 2025 across 19 reported records.
Kerecis Limited accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Ozempic, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 258 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kerecis Limited | Unresolved — no canonical attribution shown | $172.91 | 28.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $138.95 | 22.6% | 7 | 2025 |
| Advanced Oxygen Therapy Inc. | Unresolved — no canonical attribution shown | $119.07 | 19.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.63 | 8.7% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $31.76 | 5.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.14 | 2.9% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.04 | 2.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.82 | 2.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.82 | 2.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.78 | 2.6% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $14.08 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $616.00 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $172.91 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $172.91 | 1 | 2025 |
Source payment records
|
|||||
| Topical Oxygen Chamber for extremities Normalized: topical oxygen chamber for extremities |
Device | Advanced Oxygen Therapy Inc. | $119.07 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $73.47 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $73.47 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $73.47 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $65.48 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $53.63 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $53.63 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $52.31 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $31.76 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 11 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 258 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 130 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
148 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
68 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
214 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
86 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
111 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
130 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
258 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1027 | 258 |
| Amlodipine Besylate | Amlodipine Besylate | 990 | 241 |
| Pantoprazole Sodium | Pantoprazole Sodium | 599 | 161 |
| Levothyroxine Sodium | Levothyroxine Sodium | 568 | 146 |
| Losartan Potassium | Losartan Potassium | 544 | 141 |
| Metformin Hcl | Metformin Hcl | 478 | 127 |
| Gabapentin | Gabapentin | 477 | 112 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 456 | 127 |
| Simvastatin | Simvastatin | 433 | 111 |
| Metoprolol Succinate | Metoprolol Succinate | 378 | 98 |
| Furosemide | Furosemide | 333 | 96 |
| Omeprazole | Omeprazole | 328 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 271 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 269 | 67 |
| Eliquis | Apixaban | 258 | 42 |
| Potassium Chloride | Potassium Chloride | 247 | 64 |
| Lisinopril | Lisinopril | 239 | 65 |
| Trazodone Hcl | Trazodone Hcl | 238 | 50 |
| Sertraline Hcl | Sertraline Hcl | 230 | 52 |
| Alprazolam | Alprazolam | 226 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 219 | 70 |
| Jardiance | Empagliflozin | 214 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 212 | 83 |
| Escitalopram Oxalate | Escitalopram Oxalate | 209 | 50 |
| Meloxicam | Meloxicam | 202 | 50 |
| Tramadol Hcl | Tramadol Hcl | 195 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 192 | 47 |
| Allopurinol | Allopurinol | 185 | 39 |
| Mirtazapine | Mirtazapine | 176 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 173 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 45 |
| Carvedilol | Carvedilol | 164 | 37 |
| Glimepiride | Glimepiride | 160 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 151 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 151 | 39 |
| Farxiga | Dapagliflozin Propanediol | 148 | 27 |
| Donepezil Hcl | Donepezil Hcl | 140 | 29 |
| Famotidine | Famotidine | 138 | 39 |
| Metformin Hcl Er | Metformin Hcl | 133 | 40 |
| Ozempic | Semaglutide | 130 | 25 |
| Prednisone | Prednisone | 130 | 89 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 31 |
| Buspirone Hcl | Buspirone Hcl | 123 | 30 |
| Lorazepam | Lorazepam | 120 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 119 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 119 | 40 |
| Memantine Hcl | Memantine Hcl | 114 | 24 |
| Pregabalin | Pregabalin | 112 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 32 |
| Spironolactone | Spironolactone | 111 | 29 |
| Trulicity | Dulaglutide | 111 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 110 | 28 |
| Finasteride | Finasteride | 104 | 26 |
| Atenolol | Atenolol | 102 | 23 |
| Bupropion Xl | Bupropion Hcl | 102 | 29 |
| Montelukast Sodium | Montelukast Sodium | 102 | 21 |
| Xarelto | Rivaroxaban | 102 | 18 |
| Alendronate Sodium | Alendronate Sodium | 96 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 96 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 21 |
| Azithromycin | Azithromycin | 91 | 74 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 91 | 20 |
| Ezetimibe | Ezetimibe | 90 | 19 |
| Methocarbamol | Methocarbamol | 88 | 33 |
| Valsartan | Valsartan | 88 | 25 |
| Mounjaro | Tirzepatide | 86 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 80 | 65 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 80 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 76 | 19 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 75 | 75 |
| Pioglitazone Hcl | Pioglitazone Hcl | 75 | 14 |
| Torsemide | Torsemide | 75 | 15 |
| Ramipril | Ramipril | 73 | 18 |
| Meclizine Hcl | Meclizine Hcl | 72 | 30 |
| Warfarin Sodium | Warfarin Sodium | 70 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 68 | 51 |
| Clonidine Hcl | Clonidine Hcl | 65 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 20 |
| Clonazepam | Clonazepam | 63 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 16 |
| Lovastatin | Lovastatin | 60 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 18 |
| Promethazine Hcl | Promethazine Hcl | 59 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 13 |
| Divalproex Sodium | Divalproex Sodium | 55 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 18 |
| Levetiracetam | Levetiracetam | 54 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 27 |
| Cephalexin | Cephalexin | 51 | 41 |
| Colchicine | Colchicine | 50 | 20 |
| Myrbetriq | Mirabegron | 50 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 49 | 12 |
| Ketoconazole | Ketoconazole | 48 | 22 |
| Lamotrigine | Lamotrigine | 46 | suppressed |
| Synthroid | Levothyroxine Sodium | 46 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 45 | 16 |
| Topiramate | Topiramate | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 40 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Diazepam | Diazepam | 39 | 11 |
| Fluconazole | Fluconazole | 39 | 25 |
| Amoxicillin | Amoxicillin | 36 | 29 |
| Irbesartan | Irbesartan | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 36 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | 11 |
| Xifaxan | Rifaximin | 35 | suppressed |
| Glipizide | Glipizide | 34 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 11 |
| Eszopiclone | Eszopiclone | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 30 |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Nystatin | Nystatin | 30 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Brilinta | Ticagrelor | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 11 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 19 |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 18 |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Nystop | Nystatin | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Felodipine Er | Felodipine | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 14 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $616.00 · 19 records | Kerecis Limited | ABRYSVO, AFREZZA, AIRSUPRA, AREXVY, COMIRNATY, ELIQUIS, IMCIVREE, INSPIRE, Kerecis GraftGuide, Kerecis SurgiClose, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, SHINGRIX, TZIELD, Topical Oxygen Chamber for extremities, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error